Financial Assistance for Your Rheumatoid Arthritis Medications

Sulfasalazine (Azulfidine, Azulfidine EN-Tabs)
Celecoxib (Celebrex)
Hydrocortisone (Cortef, Hydrocortone)
Oxaprozin (Daypro)
Piroxicam (Feldene)
Methylprednisolone (Medrol)

2. ASSISTANCE FROM COPAYMENT FOUNDATIONS

A copayment is the amount an insured patient must pay for a prescription drug or an office visit at the time of service.  It is part of the cost-sharing arrangement with the health insurance company and varies depending upon the specifics of coverage.  Patients who have private insurance coverage or a Medicare Part D plan but still can’t afford the copays or deductibles for the expensive medications they need are considered UNDERINSURED.

Since 2003, a number of independent, charitable organizations have been established to assist the underinsured patient in meeting this specific financial need.  The drug companies make contributions to each organization which then independently administer the assistance to medically and financially qualified patients according to their own criteria and resources.

Each of the following non-profit organizations maintain segregated disease funds, including ones for RHEUMATOID ARTHRITIS, from which awards are made.  When the resources of a particular fund become too low, applications will not be accepted until sufficient funds become available.  This means that you may need to bounce back-and-forth between organizations looking for assistance and may even have to wait until a program opens up to new or renewing patients.

The Chronic Disease Fund (CDF)
The Chronic Disease Fund supports patients with chronic disease, cancers or life-altering conditions and provides financial assistance for FDA-approved specialty therapeutics used to treat those diseases. We maintain separate Disease Trusts with segregated funds, and the Fund exclusively defines the disease states and the specialty therapeutics covered using our proprietary guidelines.  Financial eligibility guidelines are not disclosed.

Program currently includes Enbrel and Humira for the treatment of Rheumatoid Arthritis.

Chronic Disease Fund

6900 N. Dallas Parkway, Suite 200, Plano, TX 75024

Phone: (877) 968-7233 or (972) 608-7141

Email: info@cdfund.org
Program website: http://www.cdfund.org/

Patient Access Network Foundation (PANF)
The Patient Access Network Foundation helps to pay for medical expenses including: medications, co-payments, insurance premiums and other out-of-pocket health care costs.  Patient should be insured and insurance must cover the medication for which patient seeks assistance.  The medication must fight the disease directly.  Patient must be a legal U.S. resident.  Patient’s family income must fall below 300% Federal Poverty Level.  Maximum Award: $4000

Program currently includes Ansaid, Arava, Azulfidine entabs, Celebrex, Cataflam, CellCept, Clinoril, Cytoxan, Enbrel, Humira, Imuran, Indocin, Kineret, Leukeran, Lodine, Methotrexate, Minocin, Mobic, Naprosyn, Neoral, Orencia, Plaquenil, Prednisone, Remicade, Rheumatrex, Rituxan, Trexall, Voltaren.